Drug Type Small molecule drug |
Synonyms 双利司他, CUDC 908, CUDC-908 + [2] |
Target |
Mechanism HDAC inhibitors(Histone deacetylase inhibitors), Phosphatidylinositol 3-kinase family inhibitors |
Therapeutic Areas |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhaseNDA/BLA |
First Approval Date- |
RegulationPriority Review (CN), Breakthrough Therapy (CN) |
Molecular FormulaC23H28Cl3N9O3S |
InChIKeyXQJBSJNJWWXTFM-UHFFFAOYSA-N |
CAS Registry1646906-27-5 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Diffuse large B-cell lymphoma recurrent | NDA/BLA | CN | 09 Oct 2023 | |
Diffuse large B-cell lymphoma recurrent | NDA/BLA | CN | 09 Oct 2023 | |
Diffuse large B-cell lymphoma refractory | NDA/BLA | CN | 09 Oct 2023 | |
Diffuse large B-cell lymphoma refractory | NDA/BLA | CN | 09 Oct 2023 | |
Non-Small Cell Lung Cancer | Phase 2 | CN | 28 Mar 2022 | |
Hormone receptor positive HER2 negative breast cancer | Phase 2 | CN | 23 Feb 2022 | |
Peripheral T-Cell Lymphoma | Phase 2 | CN | 16 Aug 2021 | |
Chronic Lymphocytic Leukemia | Phase 2 | CN | 12 Aug 2021 | |
Follicular Lymphoma | Phase 2 | CN | 12 Aug 2021 | |
Marginal Zone B-Cell Lymphoma | Phase 2 | CN | 12 Aug 2021 |
NCT06074107 (NEWS) Manual | Phase 2 | - | qvczzvleuk(phchyqvfcw) = qzqmyftgkl jllxivrzfv (grwcrrzslc ) | Positive | 20 Jul 2023 |